Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has caused 347,192 deaths around the world. The current evidence showed that severely ill patients tend to have a high concentrati...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 11; p. 1708
Main Authors:	Tang, Yujun, Liu, Jiajia, Zhang, Dingyi, Xu, Zhenghao, Ji, Jinjun, Wen, Chengping
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 10.07.2020
Subjects:	Adrenal Cortex Hormones - therapeutic use Animals Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use antimalarial agents Antimalarials - therapeutic use Artesunate - therapeutic use Betacoronavirus - immunology Coronavirus Infections - drug therapy Coronavirus Infections - immunology Coronavirus Infections - virology COVID-19 cytokine storm Hemoperfusion - methods Humans Hydroxychloroquine - therapeutic use Immunoglobulins, Intravenous - therapeutic use Immunology immunoregulation Interleukin-6 - antagonists & inhibitors Interleukin-6 - metabolism Mice Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - immunology Pneumonia, Viral - virology Programmed Cell Death 1 Receptor - antagonists & inhibitors SARS-CoV-2 tocilizumab treatment strategies COVID-19 immunoregulation antimalarial agents tocilizumab treatment strategies cytokine storm
ISSN:	1664-3224, 1664-3224
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!